Bioventix PLC

LSE BVXP.L

Bioventix PLC Capital Expenditure for the year ending June 30, 2024: USD -20.13 K

Bioventix PLC Capital Expenditure is USD -20.13 K for the year ending June 30, 2024, a -49.88% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Bioventix PLC Capital Expenditure for the year ending June 30, 2023 was USD -13.43 K, a 6.15% change year over year.
Bioventix PLC Capital Expenditure for the year ending June 30, 2022 was USD -14.31 K, a 96.02% change year over year.
Bioventix PLC Capital Expenditure for the year ending June 30, 2021 was USD -359.98 K, a 14.52% change year over year.
Bioventix PLC Capital Expenditure for the year ending June 30, 2020 was USD -421.10 K, a -292.47% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

LSE: BVXP.L

Bioventix PLC

CEO	Mr. Peter John Harrison MA
IPO Date	April 29, 2014
Location	United Kingdom
Headquarters	27–28 Eastcastle Street
Employees	12
Sector	Healthcare
Industries Biotechnology 3D Printing Cosmetics Personal Care Pet Food Pharmaceuticals

Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

Key trends

Past 5 years